Cargando…

CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis

INTRODUCTION: Enhanced B cell activity, particularly memory B cells have gained interest in evaluating response during therapies with biologics. CD27-IgD- double-negative (DN) B cells lacking the conventional memory marker CD27 are reported to be part of the memory compartment, however, only scarce...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmood, Zafar, Muhammad, Khalid, Schmalzing, Marc, Roll, Petra, Dörner, Thomas, Tony, Hans-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415279/
https://www.ncbi.nlm.nih.gov/pubmed/25888920
http://dx.doi.org/10.1186/s13075-015-0580-y
_version_ 1782369045820997632
author Mahmood, Zafar
Muhammad, Khalid
Schmalzing, Marc
Roll, Petra
Dörner, Thomas
Tony, Hans-Peter
author_facet Mahmood, Zafar
Muhammad, Khalid
Schmalzing, Marc
Roll, Petra
Dörner, Thomas
Tony, Hans-Peter
author_sort Mahmood, Zafar
collection PubMed
description INTRODUCTION: Enhanced B cell activity, particularly memory B cells have gained interest in evaluating response during therapies with biologics. CD27-IgD- double-negative (DN) B cells lacking the conventional memory marker CD27 are reported to be part of the memory compartment, however, only scarce data is available for rheumatoid arthritis (RA). We therefore focused on DN B cells in RA, studied their isotypes and modulation during interleukin-6 receptor (IL-6R) inhibition by tocilizumab (TCZ). METHODS: DN B cells were phenotypically analyzed from 40 RA patients during TCZ at baseline week 12, week 24 and 1 year. A single B cell polymerase chain reaction (PCR) approach was used to study Ig receptors, V(H) gene rearrangements and specific isotypes. RESULTS: Phenotypic analysis showed a significantly expanded population of DN B cells in RA which contain a heterogeneous mixture of IgG-, IgA- and IgM-expressing cells with a clear dominance of IgG+ cells. DN B cells carry rearranged heavy chain gene sequences with a diversified mutational pattern consistent with memory B cells. In contrast to tumor necrosis factor alpha (TNF-α) inhibition, a significant reduction in mutational frequency of BCR gene rearrangements at week 12, 24 and 1 year (P <0.0001) was observed by in vivo IL-6R inhibition. These changes were observed for all BCR isotypes IgG, IgA and IgM at week 12, 24 and 1 year (P <0.0001). IgA-RF, IgA serum level and IgA+ DN B cells decreased significantly (P <0.05) at week 12 and week 24 during TCZ. Patients with a good European League Against Rheumatism (EULAR) response to TCZ had less DN B cells at baseline as compared to moderate responders (P = 0.006). Univariate logistic regression analysis revealed that the frequency of DN B cells at baseline is inversely correlated to a subsequent good EULAR response (P = 0.024) with an odds ratio of 1.48 (95% confidence interval as 1.05 to 2.06). CONCLUSIONS: In RA, the heterogeneous DN B cell compartment is expanded and dominated by IgG isotype. TCZ can modulate the mutational status of DN Ig isotype receptors over 1 year. Interestingly, the frequency of DN B cells in RA may serve as a baseline predictor of subsequent EULAR response to TCZ. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0580-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4415279
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44152792015-05-01 CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis Mahmood, Zafar Muhammad, Khalid Schmalzing, Marc Roll, Petra Dörner, Thomas Tony, Hans-Peter Arthritis Res Ther Research Article INTRODUCTION: Enhanced B cell activity, particularly memory B cells have gained interest in evaluating response during therapies with biologics. CD27-IgD- double-negative (DN) B cells lacking the conventional memory marker CD27 are reported to be part of the memory compartment, however, only scarce data is available for rheumatoid arthritis (RA). We therefore focused on DN B cells in RA, studied their isotypes and modulation during interleukin-6 receptor (IL-6R) inhibition by tocilizumab (TCZ). METHODS: DN B cells were phenotypically analyzed from 40 RA patients during TCZ at baseline week 12, week 24 and 1 year. A single B cell polymerase chain reaction (PCR) approach was used to study Ig receptors, V(H) gene rearrangements and specific isotypes. RESULTS: Phenotypic analysis showed a significantly expanded population of DN B cells in RA which contain a heterogeneous mixture of IgG-, IgA- and IgM-expressing cells with a clear dominance of IgG+ cells. DN B cells carry rearranged heavy chain gene sequences with a diversified mutational pattern consistent with memory B cells. In contrast to tumor necrosis factor alpha (TNF-α) inhibition, a significant reduction in mutational frequency of BCR gene rearrangements at week 12, 24 and 1 year (P <0.0001) was observed by in vivo IL-6R inhibition. These changes were observed for all BCR isotypes IgG, IgA and IgM at week 12, 24 and 1 year (P <0.0001). IgA-RF, IgA serum level and IgA+ DN B cells decreased significantly (P <0.05) at week 12 and week 24 during TCZ. Patients with a good European League Against Rheumatism (EULAR) response to TCZ had less DN B cells at baseline as compared to moderate responders (P = 0.006). Univariate logistic regression analysis revealed that the frequency of DN B cells at baseline is inversely correlated to a subsequent good EULAR response (P = 0.024) with an odds ratio of 1.48 (95% confidence interval as 1.05 to 2.06). CONCLUSIONS: In RA, the heterogeneous DN B cell compartment is expanded and dominated by IgG isotype. TCZ can modulate the mutational status of DN Ig isotype receptors over 1 year. Interestingly, the frequency of DN B cells in RA may serve as a baseline predictor of subsequent EULAR response to TCZ. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0580-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-14 2015 /pmc/articles/PMC4415279/ /pubmed/25888920 http://dx.doi.org/10.1186/s13075-015-0580-y Text en © Mahmood et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mahmood, Zafar
Muhammad, Khalid
Schmalzing, Marc
Roll, Petra
Dörner, Thomas
Tony, Hans-Peter
CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis
title CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis
title_full CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis
title_fullStr CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis
title_full_unstemmed CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis
title_short CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis
title_sort cd27-igd- memory b cells are modulated by in vivo interleukin-6 receptor (il-6r) blockade in rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415279/
https://www.ncbi.nlm.nih.gov/pubmed/25888920
http://dx.doi.org/10.1186/s13075-015-0580-y
work_keys_str_mv AT mahmoodzafar cd27igdmemorybcellsaremodulatedbyinvivointerleukin6receptoril6rblockadeinrheumatoidarthritis
AT muhammadkhalid cd27igdmemorybcellsaremodulatedbyinvivointerleukin6receptoril6rblockadeinrheumatoidarthritis
AT schmalzingmarc cd27igdmemorybcellsaremodulatedbyinvivointerleukin6receptoril6rblockadeinrheumatoidarthritis
AT rollpetra cd27igdmemorybcellsaremodulatedbyinvivointerleukin6receptoril6rblockadeinrheumatoidarthritis
AT dornerthomas cd27igdmemorybcellsaremodulatedbyinvivointerleukin6receptoril6rblockadeinrheumatoidarthritis
AT tonyhanspeter cd27igdmemorybcellsaremodulatedbyinvivointerleukin6receptoril6rblockadeinrheumatoidarthritis